In its reference decision of 15 August 2023 (Ref.: 5 U 93/22), the Hanseatic Higher Regional Court of Hamburg ruled on the issuing of prescriptions for prescription-only medicines...

With the Unified Patent Court now stalled for at least the near future, U.S. life sciences companies will continue to face the question of where to bring patent infringement cases in Europe.

On June 26, 2025, Formycon AG ("Formycon") announced a distribution agreement with Teva Group subsidiary Ratiopharm GmbH ("Ratiopharm") for the semi-exclusive commercialization...

At the next Annual General Meeting of the German Medical Association (Deutscher Ärztetag), the current restrictions on remote treatment by German physicians will most likely be overturned.

The Regulation (EU) 2017/745 on Medical Devices (MDR) entered into force in 2017. Although most of the provisions will only apply as of 26 May 2020, the time for impact assessments ...

Last month, Germany introduced the Digital Health Service Act, which grants German patients access to reimbursable digital health applications.

A crucial step for start-ups on the road to success is ensuring that their innovations and trade secrets are adequately protected.

Life sciences-related cases started at a low level during the first years of the UPC's existence (about 25% of cases) and focused initially on the medtech sector.

The EU's pharmaceutical reform package represents the most comprehensive overhaul of the bloc's medicines framework in two decades

The UPC Munich Local Division (the LD Munich) has dismissed an infringement action relating to a medical device. It confirmed that a device can still infringe a patent, even if it is normally operated in a non-infringing way, as long as the patent-infringing use remains possible.

To establish jurisdiction, at least the plausible allegation of infringing acts in the country in question is necessary.

Investments in the health care sector are very popular since the start of the COVID-19 pandemic. In Germany, there has been a particular interest in the strong German medical technology sector...

"Just-In-Time" is a series of written interviews with experts from different backgrounds, all of whom have extensive experience with supply chains, including knowledge of current trends...

The boundary between medicinal products and medical devices remains a recurring issue for companies developing or marketing borderline products and courts, which has already been the subject of numerous decisions.

A member of the public does not bear the costs of a request for access to written pleadings and evidence...

One contrast between Europe and some other jurisdictions, notably the U.S., concerns the restrictive practice relating to patent claims for medical methods.

On 6 June 2025, the European Commission launched a targeted stakeholder consultation on the classification and regulation of high-risk artificial intelligence (AI) systems under the EU Artificial Intelligence Act (AI Act).

On March 20, 2023, the new transitional regime for medical devices in the EU and the EEA became effective when Regulation (EU) 2023/607 (the "Regulation")...

In a move to tackle the severe shortage of medicines, the German Federal Government has adopted the draft Act to Improve the Supply of Medicines and Avoid Shortages...

When assessing the requirement for a procedural security, namely the question whether the Claimant has “sufficient means” to compensate the Defendant for the legal costs incurred in the proceedings, only the financial situation of the Claimant should be taken into consideration, but not the financial situation of the holding company behind the Claimant.